The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or
recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and
pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse
Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors
for whom no further effective standard treatment is available.